Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
WEISEL K
Collezione AOU Città della Salute di Torino

Items : 21

Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies. in Annals of hematology / Ann Hematol. 2025 Mar 31. doi: 10.1007/s00277-025-06333-x.

2025
AOU Città della Salute di Torino

Costa LJ; Gay F; Landgren O; Mateos MV; Moreau P; Touzeau C; Ertel F; McFadden I; Najdi R; Weisel K;

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies. in Annals of hematology / Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-024-06143-7.

2025
AOU Città della Salute di Torino

Costa LJ; Gay F; Landgren O; Mateos MV; Moreau P; Touzeau C; Ertel F; McFadden I; Najdi R; Weisel K;

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.

2025
AOU Città della Salute di Torino

Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. in The Lancet. Oncology / Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3.

2024
AOU Città della Salute di Torino

Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; et alii...

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients. in Leukemia / Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7.

2024
AOU Città della Salute di Torino

Hillengass J; Dimopoulos MA; Scheid C; Boccadoro M; Müller-Tidow C; Graeven U; Hänel M; von Metzler I; van der Holt B; Reimer P; Fenk R; Besemer B; Dürig J; Blau IW; Beksac M; Brossart P; Mancuso K; Pantani L; Munder M; Raab MS; Zweegman S; Salwender HJ; Hielscher T; Bertsch U; Mai EK; Weisel KC; Cavo M; Sonneveld P; Goldschmidt H; et alii...

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting / Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520. doi: 10.1200/EDBK_433520.

2024
AOU Città della Salute di Torino

Rees MJ; D'Agostino M; Leypoldt LB; Kumar S; Weisel KC; Gay F;

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. in Haematologica / Haematologica. 2024 Jul 1;109(7):2337-2340. doi: 10.3324/haematol.2023.284694.

2024
AOU Città della Salute di Torino

Mateos MV; Weisel K; Terpos E; Delimpasi S; Kastritis E; Zamagni E; Delforge M; Ocio E; Katodritou E; Gay F; Larocca A; Leleu X; Otero PR; Schjesvold F; Cavo M; Dimopoulos MA;

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. in The Lancet. Oncology / Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6.

2023
AOU Città della Salute di Torino

Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P; et alii...

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. in European journal of haematology / Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.

2022
AOU Città della Salute di Torino

Larocca A; Yagci M; Robak P; Liberati AM; Galli M; Lindsay J; Oriol A; Beksac M; Salomo M; Pavic M; Dürig J; Jenner M; Corso A; Engelhardt M; Sonneveld P; Rodriguez-Otero P; White D; Anderson LD Jr; Moreau P; Weisel K; Schjesvold F; Richardson PG; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M;

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. in Annals of hematology / Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.